Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · JUBILANT PHARMOVA LTD · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
JUBILANT PHARMOVA LTD
NSE: JUBLPHARMA · BSE: 530019
NSE: JUBLPHARMA · BSE: 530019
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
JUBILANT PHARMOVA LTD
StateQ1 FY27 filed
Last close · 27 Oct 2026₹958.50
Market cap₹15.2k cr
TTM P/E · P/B · EV/EBITDA43.1 · 2.15 · 13.9
JUBILANT PHARMOVA LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 6,059 | 6,282 | 6,703 | 7,235 | 8,280 |
| EBITDA (ex other income) | 1,085 | 719 | 732 | 1,533 | 1,201 |
| margin % | 17.9 | 11.5 | 10.9 | 21.2 | 14.5 |
| Owners' profit | 414 | (61) | 77 | 839 | 399 |
| EPS, as reported (₹) | 26.00 | (3.83) | 4.87 | 52.99 | 25.15 |
| ROE % · ROCE % | 7.8 · 9.4 | (1.2) · 2.2 | 1.3 · 4.3 | 13.4 · 11.5 | 5.6 · 6.4 |
| Debt / equity (x) | 0.55 | 0.63 | 0.63 | 0.39 | 0.45 |
| Cash from operations | 838 | 661 | 971 | 1,072 | 1,227 |
| Capex | (600) | (814) | (898) | (1,116) | (1,449) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · JUBILANT PHARMOVA LTD · 28 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,123 | 2,290 | 2,229 |
| Profit before tax | 145 | 131 | 206 | 155 | 190 | 94 | 176 | 86 |
| Net profit | 103 | 101 | 151 | 103 | 120 | 56 | 119 | 56 |
| EPS (₹) | 6.47 | 6.37 | 9.71 | 6.49 | 7.59 | 3.52 | 7.55 | 3.57 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Radiopharma | 3,690 | 44.0 |
| Allergy Immunotherapy | 796 | 9.5 |
| Contract Development and Manufacturing Organisation - Sterile Injectables | 1,420 | 16.9 |
| Contract Research, Development and Manufacturing Organisation | 954 | 11.4 |
| Generics | 774 | 9.2 |
| Unallocable corporate | 46 | 0.5 |
| CDMO- Sterile injectables | 393 | 4.7 |
| CRDMO | 311 | 3.7 |
| Unallocable Corporate | 13 | 0.2 |
| Total, before eliminations | 8,395 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,20,165 | 34.8 | 5.01 | 22.5 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,51,896 | 86.3 | 15.03 | 65.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,538 | 73.9 | 8.90 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,17,055 | 26.1 | 3.96 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,15,722 | 105.7 | 21.31 | 64.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 1,09,385 | 33.9 | 2.86 | 14.6 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,060 | 32.3 | 3.16 | 16.7 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,353 | 50.6 | 6.24 | 28.4 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 43.1 | 30.1 | 110 of 158 | 31% |
| P/B | 2.1 | 3.0 | 59 of 163 | 64% |
| ROCE | 4.7 | 10.8 | 128 of 183 | 30% |
| ROE | 5.6 | 9.8 | 113 of 166 | 32% |
| Debt / Equity | 0.5 | 0.2 | 132 of 166 | 21% |
| EBITDA margin | 12.0 | 17.5 | 108 of 165 | 35% |
| Revenue growth | 17.3 | 16.3 | 78 of 161 | 52% |
| Profit growth | (45.0) | 30.9 | 130 of 158 | 18% |
| Market cap | 15240 | 810 | 35 of 181 | 81% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · JUBILANT PHARMOVA LTD · 28 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 23 Oct 2026 · Newspaper notice on physical share transfers and shareholder details | compliance | minimal | — | — |
| 22 Oct 2026 · Newspaper ads published for Postal Ballot notice | compliance | minimal | — | — |
| 21 Oct 2026 · Postal Ballot: Approval for NCD Issuance up to Rs 2,500 crore | board shareholder meetings | low | — | — |
| 21 Oct 2026 · India Ratings assigns IND AA+/Stable to proposed ₹1,400 crore debentures | credit debt | medium | — | — |
| 14 Oct 2026 · ICRA assigns AA+ Stable rating to Jubilant Pharmova Rs 1,400cr NCDs | credit debt | medium | — | — |
| 12 Oct 2026 · Jubilant Pharmova board okays Rs 800 crore NCD private placement, seeks Rs 2,500 cr member nod | fund raising | high | — | — |
| 12 Oct 2026 · Board approves NCD issuance up to Rs 800 crore on private placement basis | fund raising | high | — | — |
| 8 Oct 2026 · Radiopharma arm to invest CAD 94.5M to double RUBY-FILL capacity | capex operations | high | — | — |
| 7 Oct 2026 · Board to consider raising funds via NCDs on Oct 12 | fund raising | high | — | — |
| 5 Oct 2026 · Routine compliance certificate for share dematerialization, Q2 FY27 | compliance | minimal | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in